Your browser doesn't support javascript.
loading
API5 confers cancer stem cell-like properties through the FGF2-NANOG axis.
Song, K-H; Cho, H; Kim, S; Lee, H-J; Oh, S J; Woo, S R; Hong, S-O; Jang, H S; Noh, K H; Choi, C H; Chung, J-Y; Hewitt, S M; Kim, J-H; Son, M; Kim, S-H; Lee, B I; Park, H-C; Bae, Y-K; Kim, T W.
Affiliation
  • Song KH; Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.
  • Cho H; Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
  • Kim S; Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, Republic of Korea.
  • Lee HJ; Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Oh SJ; Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Woo SR; Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Hong SO; Graduate School of Medicine, Korea University, Ansan, Republic of Korea.
  • Jang HS; Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.
  • Noh KH; Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
  • Choi CH; Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, Republic of Korea.
  • Chung JY; Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.
  • Hewitt SM; Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
  • Kim JH; Department of Biomedical Sciences, College of Medicine, Korea University, Seoul, Republic of Korea.
  • Son M; Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.
  • Kim SH; Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
  • Lee BI; Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.
  • Park HC; Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
  • Bae YK; Laboratory of Tumor Immunology, Department of Biomedical Sciences, Graduate School of Medicine, Korea University, Seoul, Republic of Korea.
  • Kim TW; Department of Biochemistry, Korea University College of Medicine, Seoul, Republic of Korea.
Oncogenesis ; 6(1): e285, 2017 Jan 16.
Article in En | MEDLINE | ID: mdl-28092370
ABSTRACT
Immune selection drives the evolution of tumor cells toward an immune-resistant and cancer stem cell (CSC)-like phenotype. We reported that apoptosis inhibitor-5 (API5) acts as an immune escape factor, which has a significant role in controlling immune resistance to antigen-specific T cells, but its functional association with CSC-like properties remains largely unknown. In this study, we demonstrated for the first time that API5 confers CSC-like properties, including NANOG expression, the frequency of CD44-positive cells and sphere-forming capacity. Critically, these CSC-like properties mediated by API5 are dependent on FGFR1 signaling, which is triggered by E2F1-dependent FGF2 expression. Furthermore, we uncovered the FGF2-NANOG molecular axis as a downstream component of API5 signaling that is conserved in cervical cancer patients. Finally, we found that the blockade of FGFR signaling is an effective strategy to control API5high human cancer. Thus, our findings reveal a crucial role of API5 in linking immune resistance and CSC-like properties, and provide the rationale for its therapeutic application for the treatment of API5+ refractory tumors.